Agios Pharmaceuticals Azioni (NASDAQ: AGIO)

Ultime notizie per Agios Pharmaceuticals (NASDAQ:AGIO) Azioni

Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals Inc

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Buy and maintains $58 price target.

News

Price Target

Reiteration

Analyst Ratings

AGIO

HC Wainwright & Co. Reiterates Buy on Agios Pharmaceuticals, Maintains $58 Price Target

On Thursday, Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to &lt;18 years with PK deficiency who are not regularly transfused achieved its primary <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43687696/agios-phase-3-activate-kids-study-of-mitapivat-in-children-with-pyruvate-kinase-pk-deficiency-not-" rel="noreferrer noopener">endpoint of hemoglobin response</a>.
Pyruvate kinase (PK) deficiency is&nbsp;a rare, inherited disorder that affects red blood cells.
The safety results were consistent with the safety profile for mitapivat previously observed for adult patients with PK deficiency who are not regularly transfused.
The study&#8217;s primary endpoint was hemoglobin response, defined as a ≥1.5 g/dL ​increase in hemoglobin concentration from baseline ​ sustained at two or more scheduled assessments at​ Weeks 12, 16, and 20.
<ul>
<li>In addition, the pre-specified supportive analysis based on traditional methodology comparing the hemoglobin response rate for mitapivat versus placebo provided further evidence that the primary endpoint was met.</li>
<li>31.6% (6/19) of patients in the mitapivat arm achieved a hemoglobin response compared to 0% (0/11) of patients in the placebo arm; the 95% confidence interval for the difference in hemoglobin response rates between mitapivat and placebo was >0 (95% CI=10.8% to 52.7%). </li>
<li>In addition, improvements in changes from baseline for markers of hemolysis (indirect bilirubin, lactate dehydrogenase and haptoglobin) were observed in the mitapivat arm compared to the placebo arm.</li>
</ul>
In August 2024, Agios reported topline results from the&nbsp;ACTIVATE-KidsT Phase 3 study&nbsp;of mitapivat in children aged 1 to &lt;18 years with PK deficiency <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40110159/agios-pharmaceuticals-rare-blood-disorder-drug-misses-primary-goal-in-pediatric-study-stock-slide" rel="noreferrer noopener">who are regularly transfused</a>.
<ul>
<li>In the ACTIVATE-KidsT study, 28.1% of patients in the mitapivat arm achieved the primary endpoint of transfusion reduction response, compared to 11.8% of patients in the placebo arm.</li>
<li>Transfusion-free and normal hemoglobin response were secondary endpoints in this study and were only observed in patients in the mitapivat arm.</li>
</ul>
Based on the clinically meaningful results observed in both the ACTIVATE-Kids and ACTIVATE-KidsT Phase 3 studies, Agios intends to submit a marketing application for mitapivat in pediatric patients with PK deficiency.
Concurrently, the company reported fourth-quarter Pyrukynd&nbsp;revenues of $10.7 million, up 20% sequentially, beating the consensus of $9.33 million. 223 unique patients have completed prescription enrollment forms, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43687726/agios-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-highlights" rel="noreferrer noopener">up 6% sequentially</a>.
A total of 130 patients are on PYRUKYND therapy, inclusive of new prescriptions and continued therapy.
Cash, cash equivalents, and marketable securities as of December 31, 2024, were $1.5 billion.
Price Action: AGIO stock is down 1.86% at $32.20 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43691982/iron-mountain-q4-earnings-storage-and-data-center-revenue-growth-dividend-climbs-10-strong-2025-outlook" target="_blank" rel="noreferrer noopener">Iron Mountain Q4 Earnings: Storage And Data Center Revenue Growth, Dividend Climbs 10%, Strong 2025 Outlook</a></li>
</ul>

Biotech

Earnings

Health Care

General

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years

Agios Pharmaceuticals Q4 Sales $10.70M Beat $9.33M Estimate, Net Loss Of $96.5M Vs. $95.9M YoY, Cash Balance Of $1.5B

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) reported quarterly earnings of $11.64 per share which beat the analyst consensus estimate of $11.46 by 1.57 percent. This is a 283.89 percent increase over losses of $(6.33) per share from the same period last year. The company reported quarterly sales of $36.50 million which beat the analyst consensus estimate of $35.13 million by 3.90 percent. This is a 36.07 percent increase over sales of $26.82 million the same period last year.

Agios Pharmaceuticals FY 2024 GAAP EPS $11.64 Beats $11.46 Estimate, Sales $36.50M Beat $35.13M Estimate

Agios Says ACTIVATE-Kids Phase 3 Study Of Mitapivat Met Primary Endpoint

ABNB

AENT

ALNY

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

COIN

CROX

CYBR

DDOG

DKNG

DNOW

DXCM

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

Agios Reveals Anticipated Key 2025 Milestones And Value-driving Catalysts Through 2026

The review classification for this application is Standard and the Prescription Drug User Fee Act (PDUFA) goal date is September 7, 2025.

Agios Pharmaceuticals Says FDA Accepted sNDA For PYRUKYND (Mitapivat) For Treatment Of Adult Patients With Non-Transfusion-Dependent And Transfusion-Dependent Alpha- Or Beta-thalassemia

Agios Pharmaceuticals Filing Reported FDA Approved Update To PYRUKYND For Hemolytic Anemia In Adults With Pyruvate Kinase Deficiency; US Prescribing Info Revised To Include Liver Injury Risk

Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) from Overweight to Overweight.

Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticalsto Overweight

. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease.

The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply during Monday's session after Wedbush maintained an Outperform rating on the stock and raised its price target <a href="https://www.benzinga.com/markets/equities/24/12/42505310/tesla-prepares-for-holiday-rush-tapping-into-global-supercharger-demand-to-drive-revenue-growth">from $400 to $515</a>.
Tesla shares gained 5% to $458.08 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares gained 59.6% to $1.5000.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares jumped 42.4% to $9.49.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) climbed 31.8% to $2.6950.</li>
<li>Viridian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) gained 31.8% to $23.53 after the company announced Phase 3 results for its thyroid eye disease treatment trial.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) rose 25.5% to $8.99.</li>
<li>Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) gained 24.7% to $34.45 after the company reported topline results from its Phase 2 CANYON trial of Sevasemten in individuals with Becker muscular dystrophy, with the trial meeting its primary endpoint.</li>
<li>Aehr Test Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) rose 24.2% to $14.32 after the company announced it secured a $10 million order for AI semiconductor testing.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) climbed 19.8% to $25.08. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) gained 18.4% to $7.26. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) rose 15.5% to $8.14. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) gained 13.4% to $30.99. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) gained 10.5% to $25.11. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>Asana, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NASDAQ">ASAN</a>) gained 9.5% to $26.45.</li>
<li>Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) surged 9.1% to $42.54.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) surged 7.6% to $242.06 on continued momentum from last week after the company reported earnings for the fourth-quarter.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) gained 7% to $109.62.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42507587/tesla-to-rally-around-18-here-are-10-top-analyst-forecasts-for-monday">Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday</a></li>
</ul>

Intraday Update

Markets

Movers

AEHR

ASAN

AVGO

BTDR

CIFR

EWTX

MARA

QUBT

RGTI

SGMO

TSLA

VRDN

WULF

Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday

8 analysts have shared their evaluations of Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $56.62, a high estimate of $75.00, and a low estimate of $51.00. This current average reflects an increase of 3.26% from the previous average price target of $54.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1733850120_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Agios Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$57.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$75.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$53.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$56.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Agios Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Agios Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Agios Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Agios Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AGIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Agios Pharmaceuticals analyst ratings.</a>
<h2>About Agios Pharmaceuticals</h2>
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
<h3>Key Indicators: Agios Pharmaceuticals's Financial Health</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Agios Pharmaceuticals displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 21.15%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10574.69%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 82.89%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Agios Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 73.92%. This signifies efficient management of assets and strong financial health.
Debt Management: Agios Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Agios Pharmaceuticals

RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and raises the price target from $55 to $57.

RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $57

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Sector Outperform and raises the price target from $53 to $75.

Scotiabank Maintains Sector Outperform on Agios Pharmaceuticals, Raises Price Target to $75

Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today presented positive results from the Phase 3 ENERGIZE-T study investigating mitapivat, an oral, small molecule PK activator, in adults with transfusion-dependent alpha- or beta-thalassemia. These findings were shared in an oral presentation (abstract #409) at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.
In the ENERGIZE-T trial, mitapivat demonstrated a statistically significant reduction in transfusion burden compared to placebo in patients with transfusion-dependent alpha- or beta-thalassemia, achieving its primary endpoint. Additionally, the ENERGIZE-T study met all the key secondary endpoints, with mitapivat demonstrating a statistically significant reduction in additional measures of transfusion reduction response compared to placebo. In June 2024, Agios also <a href="https://www.globenewswire.com/Tracker?data=yCZIHDR8PSvrAcYmrbhYVzXtz0qOrlBEmNLt7nN_xw6pl1Mj2AXdoy1h6DGsnSHtC9uUFdnfS-kmUwx8-iSnaOJkdU3hjhRmj1SJM6ZrLFO6iwRjg8fcimCj7_cSLjAcTUnWPq0clc5THhnffh8TSuew3ZJSODjBe9FO6EN8DPbro4Y_f9jLQwMPuUlNC79JIOX2IXMP3L7atf5mK8ExdWvum1h8-Fgpguku085aOMQ=">presented positive results</a> from the Phase 3 ENERGIZE study, which evaluated mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia.

Agios Presented At ASH, Results From Phase 3 ENERGIZE-T Study of Mitapivat; Study Achieved Primary, All Key Secondary Endpoints In Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia

Agios Pharmaceuticals Announced It Will Present New Data And Results From Its Phase 3 Study On AG-946 At The 66th American Society Of Hematology Annual Meeting In San Diego, California From December 7-10, 2024

6 analysts have shared their evaluations of Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $53.5, with a high estimate of $56.00 and a low estimate of $51.00. This current average represents a 3.17% decrease from the previous average price target of $55.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1730487646_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Alnylam Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$53.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$56.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Alnylam Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AGIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Alnylam Pharmaceuticals</h2>
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
<h3>Unraveling the Financial Story of Alnylam Pharmaceuticals</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Alnylam Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 28.35% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Alnylam Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -1115.71%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -13.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.85%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)

RBC Capital analyst Gregory Renza reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and maintains $55 price target.

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Sector Outperform and raises the price target from $51 to $53.

Scotiabank Maintains Sector Outperform on Agios Pharmaceuticals, Raises Price Target to $53

Press Releases

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios to Present at the TD Cowen 45th Annual Healthcare Conference  on March 3, 2025

Agios to Present at Upcoming Investor Conferences

Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Comments

Agios Pharmaceuticals

Notizie

Ultime notizie per Agios Pharmaceuticals (NASDAQ:AGIO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO